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When I began training in dermatol-ogy in the 1970s, I was impressed with the rapidly increasing depth 
and breadth of cutaneous research and eager to 
participate in what I imagined would soon be a 
revolution in the diagnosis and management of 
skin disease. I was fortunate to train in a depart-
ment in which recent progress in human pho-
tobiology was being translated rapidly into an 
effective new therapy for psoriasis, mycosis fun-
goides, and other T cell–mediated dermatoses 
(Parrish, 2012). I even had the good fortune to 
spend one year of my residency as the photo-
biology fellow, participating in clinical research 
and developing new therapies that became 
immediately available to patients (Gilchrest 
et al., 1976, 1977, 1979). The experience was 
highly gratifying and motivated me to obtain 
laboratory-based training following my resi-
dency to prepare for a career bridging basic dis-
coveries at the cellular and molecular level with 
improvements in patient care. Limited only by 
my imagination and work capacity, I embarked 
on just such a career.
My story could not happen today. The inabil-
ity of dermatology residents to immerse them-
selves in translational research at the most 
formative time in their careers is a great loss, not 
only to aspiring physician–scientists and clini-
cal investigators but also, and more importantly, 
to dermatology as a discipline and to our many 
patients whose diagnostic and therapeutic needs 
remain unmet.
With the best of intentions, our government, 
certifying agencies, and academic institutions 
have imposed numerous hurdles on the prepa-
ration for and conduct of translational research. 
Cumulatively these regulations and require-
ments deter all but a handful of exceptionally 
determined individuals from attempting to trans-
late discoveries from bench to bedside.
Consider the typical dermatology trainee 
who may have participated in laboratory-based 
research as a medical student, in some cases in 
the context of an MD–PhD program, suggesting 
a strong intent to mature into a physician–sci-
entist. Upon entry into a dermatology residen-
cy program, he or she is likely to be informed 
that devoting any substantial time during the 
three-year residency to research—whether 
clinical or laboratory-based—is virtually impos-
sible. In addition to the extensive and detailed 
certification requirements of the American 
Board of Dermatology, hospitals require a full 
complement of residents in patient care roles. 
Dermatology departments also rely on this clin-
ical manpower to meet their patient-care obli-
gations. As teaching hospitals and dermatology 
departments become ever more reliant on high 
patient volumes to make ends meet financially, 
the time and money required to encourage resi-
dent participation in research disappear.
Should the resident be willing to work nights 
and weekends on a clinical research proj-
ect (knowing that laboratory-based or animal 
research is usually even less compatible with 
the obligations of dermatology residency), it 
soon becomes apparent that delays are to be 
expected. First, the trainee must take a formal 
course to qualify as a clinical investigator and 
thereafter must maintain certification, usually 
with monthly reading assignments and quiz-
zes. Submission of the project proposal to the 
institutional review board and the inevitable 
revisions require months—in my own experi-
ence up to a year (a long time in the context 
of a three-year residency program). Once the 
project is approved and under way, meticulous 
and time-consuming HIPAA (Health Insurance 
Portability and Accountability Act)-compliant 
data storage is required. Of course, it is impos-
sible to argue against the intent of these safe-
guards or the necessity of covering institutional 
costs by maximizing residents’ patient-care 
roles. However, it appears that little attention 
has been paid to cost–benefit ratios or to the lost 
opportunity that results from discouraging train-
ees from participating in research early in their 
careers. I believe the cost is huge—both to the 
trainees, who will forfeit many years of profes-
sional challenges and accompanying rewards, 
and to the patients who will never benefit from 
their potential discoveries.
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To trainees, such impediments must seem the inevi-
table way of the world, integral to conducting safe, 
ethical research. They may deduce that meaningful partici-
pation in research is incompatible with obtaining a solid 
foundation in the practice of dermatology, at least during 
a three-year residency. But none of these requirements 
existed 30 years ago! Research-oriented residents, many 
of whom are today’s department chairs and accomplished 
career-long investigators, as well as highly regarded clini-
cians, routinely spent a year or more of their three-year 
dermatology residency at the bench, seeing patients under 
faculty supervision for perhaps only half a day per week 
during that time. Their research, including human-sub-
jects research, was discussed in an ongoing manner with 
appropriate faculty supervisors but did not require lengthy 
applications or approval by committees unfamiliar with the 
disease being studied or the specific techniques employed. 
In the “old days,” mistakes may have been made and study 
designs may occasionally have been flawed, but I suspect 
such errors still occur today. Importantly, however, in the 
absence of extensive regulation, a critical number of phy-
sician–scientists and clinical investigators-to-be emerged 
from their residencies fully committed to translational 
research, their enthusiasm and curiosity intact.
Over the past 30 years, a second phenomenon has dis-
couraged translational research, although happily it is now 
being addressed constructively. I refer to the core belief 
by many academics that product development is ethical-
ly and intellectually inferior to “basic” research. Related 
beliefs include the ideas that involving physicians in bring-
ing their intended treatments or diagnostic procedures to 
the clinic creates an insurmountable conflict of interest 
(Stell and Stossel, 2011); that money is the major incen-
tive for physicians or anyone else becoming involved in 
such projects; and that encouraging pharmaceutical or 
biotechnology companies to participate in research meet-
ings reduces meeting quality, introduces bias, and detracts 
from physicians’ learning. The consequence of such beliefs 
was for many years a dysfunctional separation between 
leading physician–scientists and clinical investigators and 
those best able to harness their discoveries for improving 
human health.
The 1984 Bayh–Dole Act was enacted in response to 
Congress’s realization that surprisingly little US govern-
ment–funded research resulted in new disease treatments 
or better public health. This legislation directed academic 
institutions to promote commercialization of discoveries 
made by their federally funded investigators. Motivated by 
the potentially lucrative provision of this act that institu-
tions—the owners of any intellectual property created by 
their faculty—could generate income from this process, 
academic medical centers gradually developed “technol-
ogy transfer offices” to assist investigators with patent-pro-
tecting and then licensing their discoveries to companies 
wishing to commercialize them. Although often inefficient 
and underfunded, these offices did provide assistance to 
already savvy investigators. More recently, these offices 
have also attempted to educate students and faculty in 
relevant matters. In tandem with a more progressive view 
of the product-development process by the professoriate, 
such efforts are slowly bearing fruit.
As will be described in a series of invited editorials to 
be published in JID throughout 2015, several dermato-
logic investigators have successfully participated in the 
creation of new drugs and devices based on their own 
laboratory work or are working to facilitate the translation 
process through creation of new structures or paradigms. 
As well, the Society for Investigative Dermatology (SID) 
and many other dermatologic research organizations have 
begun to reach out to industry representatives and venture 
capitalists. The SID now solicits their membership, invites 
them to annual research meetings, welcomes sponsored 
symposia, and has even initiated “speed dating” sessions 
to promote dialog between individual investigators and 
those who might commercialize their work. All these 
efforts have great potential to accelerate progress in trans-
lational research.
Translational research is a vague term used by different 
individuals and groups to mean different things (Cripe et 
al., 2005; Rubio et al., 2010). To me, the critical elements 
include conceptualizing an improvement in patient care, 
identifying a potential means of achieving that improve-
ment through one’s own research or recognizing that 
means in the work of another, demonstrating proof of prin-
ciple, and then assembling the team that will be required 
for commercialization. It is an ambitious undertaking, 
easily derailed. It cannot thrive in an environment that is 
overly distrustful or disparaging of any of the required com-
ponents. Translational research is best taken up as early as 
possible in one’s career because there is much to learn and 
many experts who need to be in the professional network 
of a successful translational researcher.
Not every dermatologist or cutaneous biologist wishes 
to participate in translational research or, indeed, research 
of any kind. I am comfortable in suggesting, however, that 
everyone in the larger dermatology community must be 
supportive of this effort. This includes those responsible 
for setting the parameters of dermatology training, those 
supervising residents, those referring patients for research 
projects, and those funding research proposals. At the insti-
tutional level, I urge consideration of the risk–benefit ratio 
when evaluating protocols that entail truly minimal risk to 
human subjects (e.g., a punch biopsy or completing a ques-
tionnaire). Benefits of rapid, hassle-free approval include 
not only conducting the research in a timely manner but 
also teaching young investigators that such research can 
involve them in a deeply gratifying process and yield inter-
esting results after a tolerable investment of time. I predict 
that even a modestly enlightened application of federal 
institutional review board regulations at teaching hospitals 
would notably promote clinical and translational research 
among investigators at all levels of seniority.
However, the primary rationale for selecting “Progress in 
Translational Research” as the JID’s 2015 theme is not to 
emphasize current barriers. For many reasons, these bar-
riers are unlikely to be mitigated in today’s medical envi-
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ronment. Rather, it is to celebrate the impressive prog-
ress being made despite the obstacles described above. 
Such progress is manifest in every issue of the Journal and 
in day-to-day patient care. May this progress continue 
and accelerate.
Barbara A. Gilchrest
Editor
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